Hepatitis B: Standard and Novel Treatment Options
Joseph C. Ahn, Joseph Ahn – 22 August 2018
Diagnostics of Hepatitis B Virus: Standard of Care and Investigational
Kathy Jackson, Stephen Locarnini, Robert Gish – 22 August 2018
Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance
Norah A. Terrault, Anna S. F. Lok, Brian J. McMahon, Kyong‐Mi Chang, Jessica P. Hwang, Maureen M. Jonas, Robert S. Brown, Natalie H. Bzowej, John B. Wong – 22 August 2018
Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance
Norah A. Terrault, Anna S. F. Lok, Brian J. McMahon, Kyong‐Mi Chang, Jessica P. Hwang, Maureen M. Jonas, Robert S. Brown, Natalie H. Bzowej, John B. Wong – 22 August 2018
Meeting the WHO and US Goals to Eliminate Hepatitis B Infection by 2030: Opportunities and Challenges
Brian J. McMahon – 22 August 2018
Epidemiology of Hepatitis B Virus Infection in the United States
Bo Hyun Kim, W. Ray Kim – 22 August 2018
Chronic Hepatitis B in Pregnancy
Tatyana Kushner, Monika Sarkar – 22 August 2018
Disease Pathways and Mechanisms of Potential Drug Targets
Marc G. Ghany, Timothy M. Block – 22 August 2018
Hyponatremia in Cirrhosis: Implications for Liver Transplantation
Michael Leise, Andrés Cárdenas – 21 August 2018 – Hyponatremia in cirrhosis is defined as a serum sodium level ≤130 mEq/L and occurs in approximately 22% of patients with cirrhosis. The appearance of hyponatremia in patients with cirrhosis portends a poor prognosis before liver transplantation (LT), independent of the Model for End‐Stage Liver Disease (MELD) score. With the development of the MELD‐sodium score, the management of hyponatremia has become more relevant than ever before.
Discovery of the Novel Entecavir‐Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis
Ronald E. Rose, Dennis Hernandez, Paul J. Falk, Karen Ericson, Nannan Zhou, Alexandra Thiry, Fiona McPhee – 21 August 2018 – Entecavir (ETV) is a first‐line therapy for chronic hepatitis B virus (HBV), demonstrating potent suppression of HBV DNA and a high barrier to viral resistance. Previous studies revealed that ETV‐resistant (ETVr) HBV DNA resulted from substitutions in the HBV reverse transcriptase (RT) at positions rtT184, rtS202, or rtM250 in combination with lamivudine resistance (LVDr) substitutions rtM204I/V±rtL180M.